<DOC>
	<DOCNO>NCT01235468</DOCNO>
	<brief_summary>The aim study evaluate safety profile tolerability infusion cord blood cell expand lab evaluate whether infusion expand cell possible expedite engraftment time transplantation .</brief_summary>
	<brief_title>Allogenic Transplantation Ex-vivo Expanded Cord Blood ( CB )</brief_title>
	<detailed_description>Stem cell transplantation curative approach patient hematological malignancy . Umbilical cord blood source stem cell transplantation patient related donor . However , adult , number stem cell single unit , may low allow engraftment , time engraftment may prolong , increase risk transplant . In study , expand part cord blood unit , lab , try increase unit size , would suitable adult , would allow safe engraftment .</detailed_description>
	<criteria>age &gt; 18 year hematological malignancy standard indication allogeneic transplantation expect survival time 12 week relate unrelated donor availability cord blood unit compatible placental blood cryopreserved least 2 different bag ; one two unit cellular content least equal minimum dose 2 x 107 nucleated cell per kilogram body weight Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Prior allogeneic transplantation Pregnant nursing woman Positive serology hepatitis B C HIV positive Left ventricular ejection fraction &lt; 50 % DLCO &lt; 50 % Psychiatric , addictive , disorder/disease compromise ability give inform consent participation study Treatment investigational drug within 4 week enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>umbilical cord blood</keyword>
	<keyword>ex vivo expansion</keyword>
	<keyword>engraftment</keyword>
	<keyword>GVHD</keyword>
</DOC>